Compare TE Connectivity plc Ordinary Shares (TEL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TE Connectivity plc Ordinary Shares vs Travere Therapeutics Inc. Common Stock — how do they compare? TE Connectivity plc Ordinary Shares trades at $210.29 (market cap $62.51B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: TE Connectivity plc Ordinary Shares is far larger — about 12.8× Travere Therapeutics Inc. Common Stock's market cap, and TE Connectivity plc Ordinary Shares pays a 1.44% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold TE Connectivity plc Ordinary Shares for 0 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TEL | TVTX | |
|---|---|---|
Market Cap | $62.51B | $4.88B |
Volume | 2,249,319 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $249.00 | $67.52 |
52-Week Low | $195.84 | $26.79 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $66.90B | $5.01B |
Dividend Yield | 1.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TE Connectivity (TEL) trades at $215.92, down 0.63% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, 15.61% net margin, and improving cash flow. Recent analyst upgrades highlight growth potential as the company prepares for Q4 2026 earnings on October 28.
TEL offers solid investment appeal with 23.54% ROE and 48% analyst buy ratings, though near-term volatility may persist. The $253.22 consensus target implies 17% upside, supported by operational strength and dividend stability. Key risks include market sensitivity and execution challenges in competitive electronics components sector.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TE Connectivity plc Ordinary Shares
TE Connectivity designs and manufactures connectivity and sensor solutions. Its products support transportation, energy networks, industrial automation, communications infrastructure, and medical technology.
Read more on TEL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
